Rapid Reversal of Anticoagulation

Treatment for Intracerebral hemorrhage

Typical Dosage: PCC (25-50 IU/kg), Vitamin K (5-10 mg IV), Idarucizumab (5g IV), Andexanet Alfa (bolus + infusion)

Effectiveness
90%
Safety Score
60%
Clinical Trials
3
Participants
8K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
PCC (25-50 IU/kg), Vitamin K (5-10 mg IV), Idarucizumab (5g IV), Andexanet Alfa (bolus + infusion)
Time to Effect
Immediate (minutes to hours)
Treatment Duration
Single dose or short course
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$8,000
Monitoring:$200
Side Effect Mgmt:$500
Total Annual:$8,700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$34,800
Rapid Reversal of Anticoagulation Outcomes

for Intracerebral hemorrhage

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+90%
Common Side Effects
Thrombotic events (DVT, PE, MI, stroke)
+8%
Allergic reactions
+1%

Sources:

clinician.com
tctmd.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
2 active trials recruiting for Rapid Reversal of Anticoagulation in Intracerebral hemorrhage

International Care Bundle Evaluation in Cerebral Hemorrhage Research

NCT06429332RECRUITINGPHASE4
View Study
3.5K participants
INTERVENTIONAL
Oklahoma City, United States +51 more
Started: Jan 7, 2025

Maximal Medical Treatment of Intracerebral Haemorrhage Pilot Trial - MAX-ICH Pilot Trial

NCT06648369NOT YET RECRUITINGNA
View Study
50 participants
INTERVENTIONAL
Bern, Switzerland
Started: Dec 1, 2024
Completed Clinical Trials
1 completed trial for Rapid Reversal of Anticoagulation in Intracerebral hemorrhage

The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial

NCT03209258COMPLETEDNA
View Study
7.07K participants
INTERVENTIONAL
Chengdu, China
Started: Dec 12, 2017